title: Inhaled non-steroid anti-inflammatories for children and adults with bronchiectasis.
abstract: BACKGROUND
  Chronic neutrophilic inflammation, in both the presence and absence of infection, is a feature of bronchiectasis in adults and children. The anti-inflammatory properties of non-steroid anti-inflammatory drugs (NSAIDs) may be beneficial in reducing airway inflammation, thus potentially improving lung function and quality of life in patients with bronchiectasis.
  
  
  OBJECTIVE
  To evaluate the efficacy of inhaled NSAIDs in the management of non-cystic fibrosis bronchiectasis in children and adults:• during stable bronchiectasis; and• for reduction of:∘ severity and frequency of acute respiratory exacerbations; and∘ long-term pulmonary decline.
  
  
  METHODS
  We searched the Cochrane Airways Group Trials Register, which includes reports identified from the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE and the Cumulative Index to Nursing and Allied Health Literature (CINAHL). We also searched the trial registry ClinicalTrials.gov and the World Health Organization (WHO) trial portal. We carried out the latest searches on 22 September 2015.
  
  
  METHODS
  All randomised controlled trials comparing inhaled NSAIDs versus a control (placebo or usual treatment) in children or adults with bronchiectasis not related to cystic fibrosis.
  
  
  METHODS
  We reviewed the results of searches against predetermined criteria for inclusion.
  
  
  RESULTS
  One small, short-term trial was eligible for inclusion. We included this study of 25 adults with chronic lung disease (only 32% of people included in the trial had bronchiectasis), as the other conditions were linked to development of bronchiectasis, and all were characterised by chronic sputum production. We were not able to obtain separate data for people with a diagnosis of bronchiectasis. We judged that the study was at a high risk of selection bias.The primary outcome (mean difference in control of bronchiectasis severity, quality of life (Qol), cough scores) was not reported in the included study. The single trial in adults reported a significant reduction in sputum production over 14 days for the treatment group (inhaled indomethacin) compared with the placebo group (mean difference (MD) -75.00 g/day; 95% confidence interval (CI) -134.61 to -15.39) and a significant improvement in the Borg Dyspnoea Scale score (MD -1.90, 95% CI -3.15 to -0.65). We noted no significant differences between groups in lung function or blood indices and no reported adverse events.
  
  
  CONCLUSIONS
  No new studies of adults or children have been conducted since the last version of this review was published. Therefore, final conclusions have not changed. Current evidence is insufficient to support or refute the use of inhaled NSAIDs for the management of bronchiectasis in adults or children. One small trial reported a reduction in sputum production and improved dyspnoea among adults with chronic lung disease who were treated with inhaled indomethacin, indicating that additional studies on the efficacy of NSAIDs for treatment of patients with bronchiectasis are warranted.
authors.affiliation: Child Health Division, Menzies School of Health Research, Charles Darwin University, Royal Darwin Hospital Campus, Darwin, Northern Territory, Australia, 0811.
authors.forename: Susan J
authors.initials: SJ
authors.lastname: Pizzutto
authors.forename: John W
authors.initials: JW
authors.lastname: Upham
authors.forename: Stephanie T
authors.initials: ST
authors.lastname: Yerkovich
authors.forename: Anne B
authors.initials: AB
authors.lastname: Chang
mesh_terms: D000280:Administration, Inhalation; D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage*; D001987:Bronchiectasis / Q000188:drug therapy*; D002648:Child; D004417:Dyspnea / Q000188:drug therapy; D006801:Humans; D013183:Sputum / Q000378:metabolism
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal
references.citation: Thorax. 2000 Aug;55(8):635-42
references.pmid: 10899238
references.citation: Thorax. 2008 Mar;63(3):269-76
references.pmid: 18308962
references.citation: Am J Respir Crit Care Med. 1999 Apr;159(4 Pt 1):1228-33
references.pmid: 10194170
references.citation: COPD. 2005 Mar;2(1):105-10
references.pmid: 17136970
references.citation: Treat Respir Med. 2005;4(2):117-22
references.pmid: 15813663
references.citation: Eur J Respir Dis Suppl. 1986;147:6-15
references.pmid: 3533593
references.citation: Pediatr Pulmonol. 2001 Aug;32(2):175-8
references.pmid: 11477735
references.citation: BMJ. 2003 Sep 6;327(7414):557-60
references.pmid: 12958120
references.citation: Eur Respir J. 1995 Sep;8(9):1479-87
references.pmid: 8575572
references.citation: Am J Respir Crit Care Med. 2004 May 1;169(9):1028-33
references.pmid: 14977622
references.citation: J Appl Physiol (1985). 2002 Jan;92(1):155-61
references.pmid: 11744655
references.citation: Respiration. 2005 May-Jun;72(3):233-8
references.pmid: 15942290
references.citation: Heart Lung. 2006 Jan-Feb;35(1):58-65
references.pmid: 16426936
references.citation: Sarcoidosis Vasc Diffuse Lung Dis. 2002 Jun;19(2):154-9
references.pmid: 12102612
references.citation: Chron Respir Dis. 2008;5(3):161-8
references.pmid: 18684792
references.citation: Am Rev Respir Dis. 1992 Mar;145(3):548-52
references.pmid: 1546834
references.citation: Chest. 2005 Aug;128(2):739-45
references.pmid: 16100162
references.citation: Cochrane Database Syst Rev. 2013 Jun 13;(6):CD001505
references.pmid: 23765216
references.citation: Respir Med. 2008 Aug;102(8):1140-4
references.pmid: 18585027
references.citation: Eur Respir J. 1997 Dec;10(12):2784-7
references.pmid: 9493661
references.citation: Cochrane Database Syst Rev. 2007 Oct 17;(4):CD006427
references.pmid: 17943909